|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Alberta Health Services |
|---|---|
| Information provided by: | Alberta Health Services |
| ClinicalTrials.gov Identifier: | NCT00469196 |
Purpose
Mesothelioma is an incurable cancer involving the lining of the lung. Patients usually suffer progressive symptoms of shortness of breath and chest pain, until they ultimately succumb to the disease. While a very small number of patients qualify for aggressive treatment with surgery, chemotherapy and radiation, and enjoy long-term survival, the vast majority of patients have incurable disease. The treatment options currently available, including chemotherapy and radiation treatment, are only modestly effective at alleviating symptoms and improving life expectancy. This trial explores the use of new radiation technology (tomotherapy), to treat mesothelioma more aggressively than has been possible before. Tomotherapy's ability to treat unusual shaped tumours, particularly when they are wrapped around sensitive normal tissues (the lung), enable higher doses of radiation to be used and this may improve its effectiveness. We will treat 17 patients with tomotherapy and assess the breathing, symptoms, and quality of life of the patients before and after treatment
| Condition | Intervention | Phase |
|---|---|---|
|
Mesothelioma |
Procedure: Tomotherapy |
Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Tomotherapy Treatment for Mesothelioma |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Rufus Scrimger, MD | 780-432-8517 | rufusscr@cancerboard.ab.ca |
| Canada, Alberta | |
| Cross Cancer Institute | Recruiting |
| Edmonton, Alberta, Canada, T5N 2R8 | |
| Contact 780-432-8517 clinical_trials_cci@cancerboard.ab.ca | |
| Principal Investigator: Rufus Scrimger, MD | |
| Principal Investigator: | Rufus Scrimger, MD | Alberta Health Services |
More Information
| ClinicalTrials.gov Identifier: | NCT00469196 History of Changes |
| Other Study ID Numbers: | LU-11-0077 |
| Study First Received: | May 2, 2007 |
| Last Updated: | February 8, 2010 |
| Health Authority: | Canada: Health Canada |
|
mesothelioma tomotherapy |
|
Mesothelioma Adenoma Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Neoplasms Neoplasms, Mesothelial |